This has reference to our letter dated May 13, 2026, The Board of Directors of the Company at their meeting held on May 29, 2026 have resolved as follows: Pursuant to Regulation 33 of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Transgene Biotek reported audited FY2026 results with revenue from operations declining to Rs 21.12L from Rs 26.07L in FY2025 — a roughly 19% drop. The company posted a net loss of Rs 165.29L, more than double the prior year's loss of Rs 67.61L. Finance costs surged to Rs 106.02L (vs Rs 24.30L), nearly quadrupling and now far exceeding total revenue. Standalone equity is deeply negative at Rs -919.98L, though the consolidated equity stands positive at Rs 837.70L largely due to the subsidiary. Auditors Vasavi & Co issued an unmodified opinion. The subsidiary in Hong Kong has not been audited for years as it has no operations; its last available figures date to 2015-16 and are carried forward. The company is under litigation with SEBI, ED, and NCLT. Cash flow from operations turned negative at Rs -1.13L compared to a positive Rs 119.58L in the prior year.
The company is burning cash with losses widening and finance costs spiralling — the standalone balance sheet has negative equity, raising serious going concern risk. The stock is likely to remain under pressure as losses continue and legal uncertainties persist.